Loading...
Loading...
StemCells
STEM today announced that the first patient with an incomplete spinal
cord injury has been enrolled in the Company's Phase I/II clinical trial in
chronic spinal cord injury and transplanted with the Company's proprietary
HuCNS-SC^® neural stem cells. The patient, a Canadian man who suffered a
thoracic spinal cord injury from a sports-related accident, was administered
the cells yesterday at Balgrist University Hospital, University of Zurich, a
world leading medical center for spinal cord injury and rehabilitation. This
is the first patient in the second cohort of the trial, which will be
comprised of four patients who retain some sensory function below the level of
trauma and are therefore considered to have an incomplete injury.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in